Clinical Trial Update: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Utidelone with AC versus Docetaxel with AC as neoadjuvant therapy for HER2-negative breast cancer is ongoing or not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AC
• DOCETAXEL (DOCETAXEL)
• Utidelone (utidelone)

Snippet

Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN